Phoenicia BioSciences’ Chief Medical Officer. Dr. Susan Perrine, has received notice of approval of a 20th US Patent, 10,111, 846 B2 awarded on October 30, 2018. This oral therapeutic prolonges survival in irradiated mice following fatal irradiation in a study conducted by AFFRI, the Armed Forces Radiobiology Institute, with only a few days’ of oral ST7S treatment. ST7S enhances recovery of white blood cells, platelets, and red blood cells after marrow suppression in several systems.
Phoenicia is seeking partners to co-develop this therapeutic.